Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 999247

The role of the acute octreotide suppression test in detecting patients with neuroendocrine neoplasms


Kruljac, Ivan; Vičić, Ivan; Blaslov, Kristina; Kolak, Zorica; Benković, Martina; Kust, Davor; Ladika Davidović, Blaženka; Tometić, Gordan; Penavić, Ivan; Dabelić, Nina et al.
The role of the acute octreotide suppression test in detecting patients with neuroendocrine neoplasms // Neuroendocrinology, 107 (2018), 3; 284-291 doi:10.1159/000492934. Epub 2018 Aug 16. (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 999247 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
The role of the acute octreotide suppression test in detecting patients with neuroendocrine neoplasms

Autori
Kruljac, Ivan ; Vičić, Ivan ; Blaslov, Kristina ; Kolak, Zorica ; Benković, Martina ; Kust, Davor ; Ladika Davidović, Blaženka ; Tometić, Gordan ; Penavić, Ivan ; Dabelić, Nina ; Vazdar, Ljubica ; Pavić, Tajana ; Vrkljan, Milan

Izvornik
Neuroendocrinology (0028-3835) 107 (2018), 3; 284-291

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Chromogranin A ; Diagnosis ; Neuroendocrine neoplasm ; Octreotide suppression test

Sažetak
BACKGROUND: Serum chromogranin A (CgA) is routinely used as a biomarker in patients with neuroendocrine neoplasms (NENs). Several conditions and comorbidities may be associated with falsely elevated CgA, often leading to extensive diagnostic evaluation, which may be costly and harmful. The aim of this study was to analyze the effectiveness of the acute octreotide suppression test (AOST) in differentiating falsely elevated serum CgA. METHODS: Our prospective study enrolled 45 patients from two different patient cohorts: (1) 29 patients with suspicion or presence of NENs (extensive workup and subsequent biopsy confirmed 16 NENs) ; (2) 16 consecutive patients admitted via the Emergency Department without NENs (non- NENs). AOST was performed after an overnight fast. Baseline CgA was measured, after which 0.25 mg of octreotide was administered subcutaneously. CgA was measured 3 and 6 h after administration. RESULTS: Baseline CgA levels were similar in NENs and non-NENs. At the end of the AOST, CgA decreased by a median of 83.3% (41.0-127.4) in non-NENs and 13.8% (0.0-43.6) in NENs (p < 0.001). In patients with increased baseline CgA, a decrease in CgA at the 6th hour of < 51.3% had 90.0% sensitivity and 88.9% specificity in detecting NENs. In patients with normal baseline serum CgA, a decrease in CgA at the 3rd hour of < 17.6% had 83.3% sensitivity and 81.8% specificity in detecting patients with NENs. The diagnostic accuracy of the AOST in the entire study population was 86.7%. CONCLUSIONS: AOST is a promising tool to increase the diagnostic accuracy of serum CgA.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove:
KBC "Sestre Milosrdnice"

Poveznice na cjeloviti tekst rada:

doi www.ncbi.nlm.nih.gov

Citiraj ovu publikaciju:

Kruljac, Ivan; Vičić, Ivan; Blaslov, Kristina; Kolak, Zorica; Benković, Martina; Kust, Davor; Ladika Davidović, Blaženka; Tometić, Gordan; Penavić, Ivan; Dabelić, Nina et al.
The role of the acute octreotide suppression test in detecting patients with neuroendocrine neoplasms // Neuroendocrinology, 107 (2018), 3; 284-291 doi:10.1159/000492934. Epub 2018 Aug 16. (međunarodna recenzija, članak, znanstveni)
Kruljac, I., Vičić, I., Blaslov, K., Kolak, Z., Benković, M., Kust, D., Ladika Davidović, B., Tometić, G., Penavić, I. & Dabelić, N. (2018) The role of the acute octreotide suppression test in detecting patients with neuroendocrine neoplasms. Neuroendocrinology, 107 (3), 284-291 doi:10.1159/000492934. Epub 2018 Aug 16..
@article{article, author = {Kruljac, Ivan and Vi\v{c}i\'{c}, Ivan and Blaslov, Kristina and Kolak, Zorica and Benkovi\'{c}, Martina and Kust, Davor and Ladika Davidovi\'{c}, Bla\v{z}enka and Tometi\'{c}, Gordan and Penavi\'{c}, Ivan and Dabeli\'{c}, Nina and Vazdar, Ljubica and Pavi\'{c}, Tajana and Vrkljan, Milan}, year = {2018}, pages = {284-291}, DOI = {10.1159/000492934. Epub 2018 Aug 16.}, keywords = {Chromogranin A, Diagnosis, Neuroendocrine neoplasm, Octreotide suppression test}, journal = {Neuroendocrinology}, doi = {10.1159/000492934. Epub 2018 Aug 16.}, volume = {107}, number = {3}, issn = {0028-3835}, title = {The role of the acute octreotide suppression test in detecting patients with neuroendocrine neoplasms}, keyword = {Chromogranin A, Diagnosis, Neuroendocrine neoplasm, Octreotide suppression test} }
@article{article, author = {Kruljac, Ivan and Vi\v{c}i\'{c}, Ivan and Blaslov, Kristina and Kolak, Zorica and Benkovi\'{c}, Martina and Kust, Davor and Ladika Davidovi\'{c}, Bla\v{z}enka and Tometi\'{c}, Gordan and Penavi\'{c}, Ivan and Dabeli\'{c}, Nina and Vazdar, Ljubica and Pavi\'{c}, Tajana and Vrkljan, Milan}, year = {2018}, pages = {284-291}, DOI = {10.1159/000492934. Epub 2018 Aug 16.}, keywords = {Chromogranin A, Diagnosis, Neuroendocrine neoplasm, Octreotide suppression test}, journal = {Neuroendocrinology}, doi = {10.1159/000492934. Epub 2018 Aug 16.}, volume = {107}, number = {3}, issn = {0028-3835}, title = {The role of the acute octreotide suppression test in detecting patients with neuroendocrine neoplasms}, keyword = {Chromogranin A, Diagnosis, Neuroendocrine neoplasm, Octreotide suppression test} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font